News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma and Protagonist Therapeutics Team Up for Peptide Drug Discovery and Development



6/18/2012 10:50:45 AM

COPENHAGEN, Denmark & MENLO PARK, Calif.--(BUSINESS WIRE)--Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company. Under the agreement, Zealand Pharma and Protagonist will join forces to identify, optimize and develop novel disulfide-rich peptides (DRPs) with the therapeutic potential to offer better treatment for patients in defined, non-disclosed disease areas.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES